全文获取类型
收费全文 | 1066篇 |
免费 | 34篇 |
国内免费 | 3篇 |
专业分类
儿科学 | 74篇 |
妇产科学 | 11篇 |
基础医学 | 79篇 |
口腔科学 | 25篇 |
临床医学 | 84篇 |
内科学 | 367篇 |
皮肤病学 | 21篇 |
神经病学 | 22篇 |
特种医学 | 257篇 |
外科学 | 42篇 |
综合类 | 15篇 |
预防医学 | 32篇 |
眼科学 | 4篇 |
药学 | 30篇 |
中国医学 | 3篇 |
肿瘤学 | 37篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 4篇 |
2018年 | 15篇 |
2017年 | 9篇 |
2016年 | 7篇 |
2015年 | 10篇 |
2014年 | 16篇 |
2013年 | 16篇 |
2012年 | 20篇 |
2011年 | 8篇 |
2010年 | 35篇 |
2009年 | 42篇 |
2008年 | 25篇 |
2007年 | 21篇 |
2006年 | 34篇 |
2005年 | 27篇 |
2004年 | 35篇 |
2003年 | 34篇 |
2002年 | 24篇 |
2001年 | 23篇 |
2000年 | 18篇 |
1999年 | 15篇 |
1998年 | 51篇 |
1997年 | 66篇 |
1996年 | 49篇 |
1995年 | 45篇 |
1994年 | 50篇 |
1993年 | 51篇 |
1992年 | 15篇 |
1991年 | 14篇 |
1990年 | 10篇 |
1989年 | 36篇 |
1988年 | 40篇 |
1987年 | 29篇 |
1986年 | 28篇 |
1985年 | 26篇 |
1984年 | 11篇 |
1983年 | 21篇 |
1982年 | 17篇 |
1981年 | 18篇 |
1980年 | 21篇 |
1979年 | 3篇 |
1978年 | 8篇 |
1977年 | 14篇 |
1976年 | 9篇 |
1975年 | 18篇 |
1973年 | 2篇 |
1971年 | 4篇 |
1948年 | 1篇 |
排序方式: 共有1103条查询结果,搜索用时 203 毫秒
71.
TAYLOR JE; CALNE RY; STEWART WK 《QJM : monthly journal of the Association of Physicians》1991,80(3):771-775
A patient with cystic kidney disease of adult onset and severecystic hepatomegaly is presented. The patient was severely disabledsolely by her abdominal bulk. Simultaneous liver and renal transplantationwas undertaken successfully. 相似文献
72.
Thymic cysts in mediastinal Hodgkin disease 总被引:3,自引:0,他引:3
Three cases of proved thymic cysts associated with mediastinal Hodgkin disease are presented. Two illustrate regression of lymphoma with chemotherapy but persistence of thymic cysts. The third case demonstrates a thymic cyst in untreated Hodgkin disease. These cases suggest that such cysts are probably neither coincidental with nor a consequence of therapy but are probably related to initial thymic involvement by Hodgkin disease. 相似文献
73.
74.
The binding and processing of monoclonal human IgG1 by cells of a human macrophage-like cell line (U937) 总被引:2,自引:0,他引:2
The goal of these experiments was to assess the relationship between the binding and processing of IgG by Fc-receptor-bearing cells. Cells of the U937 human macrophage-like cell line were incubated with 125I- labeled monomers, dimers, oligomers (composed of 2-4 IgG1 subunits), and HP (heavy polymers composed of 5 or more subunits per polymer) of monoclonal human IgG1 in vitro. Binding was assessed by spinning cells through a layer of phthalate oils. Internalization of IgG1 was assessed by quantitating residual binding to cells after surface-bound IgG was removed by a brief treatment with a solution containing 0.25 M acetic acid and 0.5 M sodium chloride. Catabolism was assessed by measuring the release of radioactive fragments of IgG1, which were not precipitated by 10% trichloroacetic acid. Unstimulated U937 bound about 10,000 molecules per cell of IgG1 monomer, with an equilibrium binding constant (Ka) of 5 X 10(8) M-1. After stimulation with a conditioned medium in vitro, binding per cell was increased 3-7--fold, and the Ka was decreased 2-4--fold. Both unstimulated and stimulated cells internalized and catabolized labeled IgG1 HP, but stimulated cells internalized and digested much more IgG1 HP per cell than unstimulated cells. Both monomers and dimers of IgG1 were internalized and degraded very slowly by stimulated cells, even though both preparations readily bound to cells. In contrast, oligomers and (to an even greater extent) IgG1 HP were internalized and degraded much more rapidly. Internalization of IgG1 HP was markedly inhibited by incubation at 4 degrees C, but not by incubation with a variety of metabolic inhibitors. Catabolism was inhibited by chloroquine and monensin (inhibitors of lysosomal acidification) and by cytochalasin (an inhibitor of microfilament polymerization). Binding to the surface of cells was not markedly inhibited by any agent tested. The capacity of cells to bind labeled IgG1 was markedly reduced by prior incubation in the presence of unlabeled IgG1. This reduction was in part due to the steric blockade of receptors caused by the avid, but reversible, binding of IgG1. In addition, IgG1 oligomers or HP (but not IgG1 monomers or dimers) also caused an irreversible reduction in the number of Fc receptors by a process analogous to receptor down-regulation, as observed in other receptor--ligand systems. 相似文献
75.
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials 总被引:18,自引:1,他引:17
De Luca G Suryapranata H Stone GW Antoniucci D Tcheng JE Neumann FJ Van de Werf F Antman EM Topol EJ 《JAMA》2005,293(14):1759-1765
Context The benefits of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) are still a matter of debate. Objective To combine data from all randomized trials conducted with abciximab in STEMI. Data Sources Formal searches of electronic databases (MEDLINE, PubMed) from from January 1990 to December 2004. Study Selection We examined all completed, published, randomized trials of abciximab in STEMI. The following key words were used for study selection: randomized trial, myocardial infarction, reperfusion, primary angioplasty, facilitated angioplasty, stenting, fibrinolysis, IIb-IIIa inhibitors, and abciximab. Data Extraction Information on study design, type and dosage of drugs, inclusion and exclusion criteria, number of patients, and clinical outcome was extracted by 2 investigators. Disagreements were resolved by consensus. Data Synthesis Eleven trials were analyzed, involving 27115 patients (12 602 [46.5%] in the abciximab group, 14 513 [53.5%] in the control group). When compared with the control group, abciximab was associated with a significant reduction in short-term (30 days) mortality (2.4% vs 3.4%, P = .047) and long-term (6-12 months) mortality (4.4% vs 6.2%, P = .01) in patients undergoing primary angioplasty but not in those treated with fibrinolysis or in all trials combined. Abciximab was associated with a significant reduction in 30-day reinfarction, both in all trials combined (2.1% vs 3.3%, P<.001), in primary angioplasty (1.0% vs 1.9%, P = .03), and in fibrinolysis trials (2.3% vs 3.6%, P<.001). Abciximab did not result in an increased risk of intracranial bleeding (0.61% vs 0.62%, P = .62) but was associated with an increased risk of major bleeding complications when combined with fibrinolysis (5.2% vs 3.1%, P<.001) but not with primary angioplasty (4.7% vs 4.1%, P = .36). Conclusions This meta-analysis shows that, when compared with the control group, adjunctive abciximab for STEMI is associated with a significant reduction in 30-day and long-term mortality in patients treated with primary angioplasty but not in those receiving fibrinolysis. The 30-day reinfarction rate is significantly reduced in patients treated with either fibrinolysis or primary angioplasty. A higher risk of major bleeding complications is observed with abciximab in association with fibrinolysis. 相似文献
76.
Cantor WJ Madan M O'Shea JC Chisholm RJ Lui HK Cohen DJ Feldman RL Green R Hellkamp AS Kitt MM Tcheng JE 《The Journal of invasive cardiology》2005,17(7):360-364
Glycoprotein (GP) IIb/IIIa inhibitors are often used as a rescue or bailout therapy to manage complications arising during percutaneous coronary intervention, rather than as prophylactic treatment. We sought to identify the characteristics and outcomes of patients requiring bailout treatment. The ESPRIT trial randomized 2,064 patients to receive eptifibatide or placebo starting immediately before percutaneous coronary intervention (PCI). Bailout therapy was used in 77 patients: 43 (4.2%) randomized to placebo and 34 (3.3%) to eptifibatide (p = 0.3). Bailout therapy for thrombosis was used more often in the placebo group (2.1% versus 1.0%; p = 0.03). Multivariable predictors of bailout included a greater than or equal to 90% stenosis, or visible thrombus on the baseline angiogram, and no aspirin pre-treatment before PCI. However, overall the model predicted bailout poorly (c-index = 0.64). The need for bailout cannot be reliably predicted using baseline characteristics. Patients experiencing complications have poor clinical outcomes despite bailout use of GP IIb/IIIa inhibitors. 相似文献
77.
78.
79.
Madhotra D Fenton JE Makura ZG Charters P Roland NJ 《Irish journal of medical science》2004,173(4):197-199
Background The timing of aggressive airway intervention in adult epiglottitis is controversial.
Aims To correlate Friedman’s staging of epiglottitis on admission with the airway interventions undertaken.
Methods A retrospective study of 23 adult patients, mean age 51 years (range 29–81 years), who had been admitted with acute supraglottitis
between March 1988 and December 2000 was undertaken.
Results Three patients (13%) had airway interventions; two with tracheostomy and one with tracheal intubation. All were Friedman
stage III and had rapid symptom progression during the 24 hours prior to admission. Three other stage III patients with symptom
progression longer than 24 hours and all the remaining patients (stage II or less) were managed with observation and intravenous
therapy.
Conclusions Friedman originally advocated airway intervention in any patient stage II or worse, but this intubation threshold should
probably be lowered to those patients with rapid-onset stage III (moderate respiratory distress, stridor, respiratory rate
>30 per minute, pCO2 >45mmHg) disease. 相似文献
80.
Sadeghi HM Grines CL Chandra HR Mehran R Fahy M Cox DA Garcia E Tcheng JE Griffin JJ Stuckey TD Lansky AJ O'Neill WW Stone GW 《The American journal of cardiology》2004,94(5):637-40, A9
In 2,082 patients in the CADILLAC trial, the outcomes of patients presenting during peak hours were compared with those presenting during peak hours (Monday to Friday 8a.m. to 8 p.m., n = 1,047, 51%) were compared with those of patients presenting during off-peak hours (weeknights from 8 p.m. to 8 a.m. and weekends, n = 989, 49%). Although treatment times to percutaneous coronary intervention (PCI) were delayed approximately 21 minutes, in patients with acute myocardial infarctions occurring on weeknights and weekends, this modest delay did not adversely affect procedural success, myocardial recovery, or survival after PCI. 相似文献